FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.
We played a lead role in drafting coalition comments on the FDA's proposed mammography guideline updates.
FORCE recommendations regarding genomics were accepted and will be integrated into the Healthy People 2030 objectives.
Today, the FDA announced a new pilot program called Project Facilitate to assist oncologists in requesting access to unapproved therapies for cancer patients.
We signed onto coalition letters to the House and Senate regarding FY20 funding for the Defense Health Research programs.
FORCE submitted a letter of support for TX legislation that would mandate coverage of fertility preservation prior to cancer-related surgery or treatment.
On March 6, 2018, the Food and Drug Administration (FDA) announced approval of a new direct-to-consumer genetic test for three BRCA mutations most commonly found in people with Ashkenazi Jewish (Eastern European) ancestry, often referred to as founder mutations. With thousands of known BRCA mutations, 23andMe’s “Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants)” provides consumers with an extremely limited snapshot of potential hereditary cancer risk.